Hepatocellular toxicity is a putative side-effect of amiodarone. The hepatic detoxification enzyme glutathione S-transferase-A1-1 (GSTA1-1) is a sensitive indicator of hepatocellular damage. We investigated the occurrence of subclinical liver injury, as measured by plasma GSTA1-1 in intensive care unit patients with atrial fibrillation receiving amiodarone.
Amiodarone is a class III antiarrhythmic drug frequently used in the intensive care unit (ICU) to treat supraventricular and ventricular arrhythmias. Although amiodarone is an effective drug to prevent 1 and treat 2 atrial fibrillation in postoperative and critically ill patients, the incidence and degree of the potential adverse effects are not well known in the ICU population. Chronic use of amiodarone is associated with adverse events like thyroid dysfunction, pulmonary and hepatic toxicity. Much less attention has been given to the acute toxic effects, although acute pulmonary and hepatocellular toxicity has been described [3] [4] [5] [6] .
During long-term administration of amiodarone an asymptomatic rise in liver enzymes occurs in 25% of patients, while hepatic injury after intravenous loading with amiodarone is less well known. Bravo et al 7 described three patients with acute hepatocellular toxicity and 25 patients from the literature in whom most patients showed a rise in liver enzymes within 24 hours. Twenty-five of the 28 published patients had transaminases exceeding 10 times the upper limit of normal.
Different mechanisms of hepatocellular toxicity of intravenous amiodarone have been postulated: liver ischaemia due to impaired hepatic perfusion as a result of its well known cardiovascular effects 8, 9 , immunomediated centrilobular necrosis and inhibition of cytochrome P 450 isenozymes which leads to elevation of the plasma concentrations of other hepatotoxic medications 10 . Another hypothesis is that the cosolvent polysorbate 80, used to solubilise amiodarone, has hepatotoxic effects 11 . The membrane fluidisation potential of polysorbate 80 might impair hepatic cell integrity and increase permeability of hepatocytes. These mechanisms may lead to subclinical hepatic injury that is not detected by standard laboratory methods. recent studies have shown that the cytosolic liver enzyme glutathione S-transferase-A1-1 (GSTA1-1) may be a far more sensitive indicator of hepatocellular damage 12,13 than the transaminases. It is more uniformly distributed throughout the liver cell, has a higher cytosolic concentration and has a half-life of approximately one hour, which may make it good marker for early liver injury.
The aim of the present study is to investigate the putative acute subclinical hepatotoxic effect of amiodarone infusion in haemodynamically stable ICu patients with atrial fibrillation.
MATerIAlS AND MeTHODS

Patients
The local ethics committee approved the conduct of the present study, and since the indication for amiodarone was based on clinical grounds, waived the need for informed consent. This prospective study was set in the multi-disciplinary intensive care unit of the radboud university Nijmegen Medical Centre, The Netherlands.
We studied 16 consecutive ICu patients with atrial fibrillation who were haemodynamically stable, defined as systolic blood pressure >90 mmHg, diuresis of more than 20 ml per hour and stable vasopressor therapy. Patients who had pre-existent liver failure, hepatitis, HellP syndrome or more than two-fold elevation of liver transaminases at baseline were excluded.
Acute Physiology and Chronic Health evaluation (APACHe) II data were collected for each patient for the first 24 hours after admission. Heart rate was continuously monitored using a 3-lead eCG. A radial artery catheter was sited for arterial blood sampling as well as continuous blood pressure monitoring. Blood pressure was analysed every 15 minutes during the first hour after the administration of amiodarone, thereafter every half hour until four hours and every hour until 24 hours were completed.
Patients received amiodarone 150 mg intravenously over 15 minutes. When no sinus rhythm occurred, this dose was repeated after 15 minutes, followed by continuous infusion of amiodarone 1200 mg per 24 hours.
Measurements of liver injury
Alanine aminotransferase (AlT), aspartate aminotransferase (AST) and bilirubin at t=0, six, 12 and 24 hours were determined immediately by Aeroset (Abbott, Hoofddorp, The Netherlands). Since GSTA1-1 has a significantly lower half-life in the circulation (approximately one hour) it was measured at t=zero, one, three, six, 12 and 24 hours after the administration of amiodarone. Plasma was processed immediately by centrifugation at 2000 g at 4°C for 15 minutes and was stored at -80°C before analysis. GSTA1-1 was assayed by elISA as described previously 14 . each sample was analysed in triplicate.
Data analysis, calculations and statistics
The effects of amiodarone were analysed by comparing baseline variables and the timedependent changes by one-way analysis of variance with repeated measures. Power-analysis was based on a presumed standard deviation of 15% of the measured endpoints. A change of 10% was considered clinically relevant. With an alpha=0.05, we calculated that a sample size of 14 would be needed to achieve a power of 80%. Therefore, 16 patients were included. Normally distributed data are expressed as mean ± SeM, whereas the other data are expressed as median (range). A P value of <0.05 was considered statistically significant.
reSulTS
Patients
Patient characteristics are presented in Table 1 . All patients were mechanically ventilated. Twelve of 16 patients received two loading doses of amiodarone 150 mg and 1200 mg for 24 hours, three received amiodarone 150 mg and 1200 mg for 24 hours and one patient received amiodarone 150 mg loading dose only because of conversion into sinus rhythm. Median (range) cumulative amiodarone dose was 1450 (150 to 1500) mg.
Effects of amiodarone on haemodynamic parameters
Blood pressure increased from 125±8/60 ±3 mmHg (mean ± SeM) at t=0 to 144±9/ 66±4 mmHg at t=24 hours (P <0.05), whereas heart rate decreased from 124±5 to 86±6 beats per minute (P <0.05). Median time to sinus rhythm was 4.75 hours (range 0.1 to 20 hours). All patients converted into sinus rhythm, only one patient had a relapse of atrial fibrillation within 24 hours at t=20 hours. None of the patients showed haemodynamic instability during the administration of amiodarone.
Effects of amiodarone on GSTA1-1, liver transaminases and bilirubin
As illustrated in Figure 1 , amiodarone induced no significant elevation of GSTA1-1, AlT, AST or bilirubin during the observation period of 24 hours.
DISCuSSION
The present study demonstrates that intravenous administration of amiodarone in haemodynamically stable ICu patients with atrial fibrillation is effective and does not cause an increase in GSTA1-1, as a marker of subclinical hepatocellular toxicity.
In all previous studies investigating the hepatocellular toxicity of amiodarone, hepatocellular damage was determined by the rise of the liver transaminases. AlT and AST are mainly located in the periportal hepatocytes. In contrast, hepatocellular damage due to amiodarone is mainly located in the centrilobular hepatocytes 15, 16 implying that AST and AlT may be poor markers for amiodarone-induced liver injury. Furthermore, the relatively long half-life of AST and AlT makes it difficult to interpret the cause-effect relation of the possible hepatocellular toxicity of a loading dose of amiodarone. Prior research showed that GSTA1-1 is a reliable marker of hepatocellular damage in patients with chronic hepatitis C infection 17 , HellP syndrome 18 , cystic fibrosis 19 and liver transplantation 20, 21 . In some of these patient groups, GSTA1-1 was elevated up to 80 times the upper limit of normal. Also, changes in GSTA1-1 concentrations are used to examine pharmacological hepatic toxicity 22 . As we did not find any elevation of GSTA1-1, we conclude that amiodarone does not induce subclinical hepatic injury.
Since we studied a relatively small group of patients, our finding that amiodarone does not increase GSTA1-1 levels does not exclude the immunological pathway, because this phenomenon is very rare. Also, our study does not exclude the possible influence of amiodarone-induced changes in haemodynamics, as these did not occur in the studied patient group. Nevertheless, the absence of subclinical hepatic injury in our study excludes the last putative pathophysiological mechanism of liver injury mediated by direct toxicity of the cosolvent polysorbate 80. Polysorbate 80 is a surfactant which acts as emulgator for the lipophilic amiodarone. This membrane fluidisation effect of polysorbate 80 23 might influence the hepatic cell integrity which causes leakage of liver enzymes. Nevertheless, our study showed that this mechanism does not result in elevation of GSTA1-1 in critically ill patients with atrial fibrillation.
CONCluSION
Acute liver failure induced by amiodarone is a potentially fatal side-effect of which the pathophysiologic mechanism is not clear. Direct hepatic toxicity of the cosolvent polysorbate is thought to play an important role. Our study shows that there is no amiodarone-induced increase in GSTA1-1 in critically ill patients with atrial fibrillation. Since plasma GSTA1-1 is a highly sensitive indicator of hepatocellular damage, our study shows that amiodarone-polysorbate 80 administration does not result in subclinical hepatocellular toxicity in this small group of diverse patients. In our group of patients, amiodarone did not induce hypotension. It is important to realise that rare immunological reasons for the occurrence of amiodarone-induced liver injury cannot be excluded by our study.
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